JW (Cayman) Therapeutics Co. Ltd
HKEX:2126.HK
1.47 (HKD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 173.856 | 145.702 | 30.797 | 0 | 5.483 | 0.215 |
| Cost of Revenue
| 85.637 | 86.946 | 21.752 | 0 | 0 | 0 |
| Gross Profit
| 88.219 | 58.756 | 9.045 | 0 | 5.483 | 0.215 |
| Gross Profit Ratio
| 0.507 | 0.403 | 0.294 | 0 | 1 | 1 |
| Reseach & Development Expenses
| 413.616 | 407.818 | 414.397 | 225.215 | 136.107 | 75.989 |
| General & Administrative Expenses
| 64.501 | 179.763 | 201.518 | 231.294 | 72.892 | 20.548 |
| Selling & Marketing Expenses
| 53.25 | 190.877 | 170.732 | 13.268 | 0 | 0 |
| SG&A
| 117.751 | 370.64 | 372.25 | 244.562 | 72.892 | 20.548 |
| Other Expenses
| 0.246 | -0.853 | -0.558 | 0 | 0 | -45.751 |
| Operating Expenses
| 658.611 | 914.639 | 716.977 | 1,666.474 | 639.209 | 117.033 |
| Operating Income
| -789.607 | -697.175 | -771.716 | -467.86 | -203.516 | -112.232 |
| Operating Income Ratio
| -4.542 | -4.785 | -25.058 | 0 | -37.118 | -522.009 |
| Total Other Income Expenses Net
| -197.85 | -148.96 | 69.388 | -1,195.943 | -429.741 | -160.384 |
| Income Before Tax
| -767.996 | -846.135 | -702.328 | -1,663.803 | -633.257 | -272.616 |
| Income Before Tax Ratio
| -4.417 | -5.807 | -22.805 | 0 | -115.495 | -1,267.981 |
| Income Tax Expense
| -3.298 | 67.42 | 32.776 | 0 | 0 | 112.531 |
| Net Income
| -767.996 | -846.135 | -702.328 | -1,663.803 | -633.257 | -272.616 |
| Net Income Ratio
| -4.417 | -5.807 | -22.805 | 0 | -115.495 | -1,267.981 |
| EPS
| -1.87 | -2.06 | -1.76 | -12.61 | -9.74 | -0.72 |
| EPS Diluted
| -1.87 | -2.06 | -1.76 | -12.61 | -9.74 | -0.72 |
| EBITDA
| -473.61 | -629.527 | -738.703 | -454.041 | -194.403 | -152.059 |
| EBITDA Ratio
| -2.724 | -4.321 | -23.986 | 0 | -35.456 | -707.251 |